Skip to main content

/ Health affairs/ Group items tagged Cosentyx-FDA-approval

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

FDA Approves Cosentyx for Hidradenitis Suppurativa Relief - 0 views

www.pharmacy.biz/...radenitis-suppurativa-patients

Cosentyx-FDA-approval Hidradenitis-suppurativa-treatment IL-17A-inhibitor Cosentyx-Phase-III-results Secukinumab-for-HS Cosentyx-dosage-for-HS Novartis-drug-for-HS

shared by pharmacybiz on 09 Nov 23 - No Cached

pharmacybiz on 09 Nov 23

The US Food and Drug Administration (FDA) has approved the Novartis drug, Cosentyx, (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. HS is a chronic, progressive and painful disease which affects one in 100 people worldwide, and has limited treatment options. "Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS," said the Swiss company. The FDA approval was based on robust Phase III data (SUNSHINE and SUNRISE studies) in which Cosentyx showed rapid relief from HS symptoms as early as Week 21.

<div class="cArrow"> </div><div class="cContentInner">The US Food and Drug Administration (FDA) has approved the Novartis drug, Cosentyx, (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. HS is a chronic, progressive and painful disease which affects one in 100 people worldwide, and has limited treatment options. "Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS," said the Swiss company. The FDA approval was based on robust Phase III data (SUNSHINE and SUNRISE studies) in which Cosentyx showed rapid relief from HS symptoms as early as Week 21.</div>

...

Cancel

1 - 1 of 1

Showing 20▼ items per page

Related searches